1887

Abstract

We have expressed a number of polypeptides derived from the capsid proteins of the human parvovirus B19 in . These include native VP1 (84K) and VP2 (58K) proteins and also fusions to - galactosidase containing differing amounts of the amino terminus of the VP 1/2 polypeptide. Although each of these was expressed at high levels and the majority were produced as full-length proteins, only one was soluble. This soluble polypeptide, pi32, is a galactosidase fusion protein that includes 145 amino acids from B19 which are entirely derived from the region unique to VP1. Despite containing such a small portion of VP1, which itself constitutes only 4% of total capsid protein, p132 reacted with all our known anti-B19 IgM-positive human serum samples. We conclude that this region contains epitopes which must be prominently exposed on the intact virus. We have demonstrated the use of this recombinant antigen in a simple diagnostic assay for B19-specific antibodies which can be used for initial screening of human serum samples. In a survey of 103 serum specimens, our ELISA positively identified all samples (19/19) which were positive by IgM antibody capture radioimmunoassay. The recombinant p132 antigen is efficiently produced and readily purified from , and its use as a diagnostic antigen should increase the availability of routine clinical testing for human parvovirus infection.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-71-11-2665
1990-11-01
2021-10-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/71/11/JV0710112665.html?itemId=/content/journal/jgv/10.1099/0022-1317-71-11-2665&mimeType=html&fmt=ahah

References

  1. Anderson M. J., Davis L. R., Hodgson J., Jones .S.E., Murtaza L., Pattison J. R., Stroud C. E., White J. M. 1982; Occurrence of infection with a parvovirus-like agent in children with sickle cell anaemia during a two year period. Journal of Clinical Pathology 35:744–749
    [Google Scholar]
  2. Anderson M. J., Jones S. E., Fisher-Hoch S. P., Lewis E., Hall S. M., Bartlett C. L. R., Cohen B. J., Mortimer P. P., Periera M. S. 1983; Human parvovirus, the cause of erythema infectiosum (fifth disease)?. Lancet i:1378
    [Google Scholar]
  3. Anderson L. J., Tsou C., Parker R. A., Chorba T. L., Wulff H., Tattershall P., Mortimer P. P. 1986; Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. Journal of Clinical Microbiology 24:522–526
    [Google Scholar]
  4. Beard C., St Amand J., Astell C. R. 1989; Transient expression of B19 parvovirus gene products in COS-7 cells transfected with B19- SV40 hybrid vectors. Virology 172:659–664
    [Google Scholar]
  5. Best J. M., Banatvala J. E. 1989; Rubella. In Principles and Practice of Clinical Virology pp. 315–353 Zuckerman A. J., Banatvala J. E., Pattison J. R. Edited by Chichester: John Wiley and Sons;
    [Google Scholar]
  6. Brown T:, Ritchie L. D., Clewly J. P., Reid T. M. S. 1984; Intrauterine parvovirus infection associated with hydropsfetalis. Lancet ii:1033
    [Google Scholar]
  7. Christie G. E., Farnham P. J., Platt T. R. 1981; Synthetic sites for transcription termination and a functional comparison with tryptophan operon termination sites in vitro . Proceedings of the National Academy of Sciences, U.S.A 78:4180–4184
    [Google Scholar]
  8. Cohen B. J., Mortimer P. P., Pereira M. S. 1983; Diagnostic assays with monoclonal antibodies for the human serum parvoviruslike virus (SPLV). Journal of Hygiene 91:113–130
    [Google Scholar]
  9. Cossart Y. E., Cant B., Field A. M., Widdows D. 1975; Parvovirus-like particles in human sera. Lancet i:72–73
    [Google Scholar]
  10. Cotmore S. F., Mckie V. C., Anderson L. J., Astell C. R., Tattersall P. 1986; Identification of the major structural and non-structural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments. Journal of Virology 60:548–557
    [Google Scholar]
  11. de Boer H. A., Comstock L. J., Vasser M. 1983; The tac promoter. A functional hybrid derived from the trp and lac promoters. Proceedings of the National Academy of Sciences, U.S.A 80:81–86
    [Google Scholar]
  12. Duncan J. R., Cappellini M. D., Anderson M. J., Potter C. G., Kurtz J. B., Weatherall D. J. 1983; Aplastic crisis due to parvovirus infection in pyruvate kinase deficiency. Lancet ii:14–16
    [Google Scholar]
  13. Hall S. M., Cohen B. J., Mortimer P. P., Caul E. O., Cradock-Watson J., Anderson M. J., Pattison J. R., Shirley J. A., Peto T. E. A. 1990; Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. British Medical Journal 1:1166–1170
    [Google Scholar]
  14. Kakigaya S., Shimada T., Fujita S., Young N. 1989; A genetically engineered cell line that produces empty capsids of B19 (human) parvovirus. Proceedings of the National Academy of Sciences, U.S.A 86:7601–7605
    [Google Scholar]
  15. Kelleher J. F., Lubon N. L. C., Mortimer P. P., Kamimura T. 1983; Human serum parvovirus: a specific cause of aplastic crisis in children with hereditary spherocytosis. Journal of Pediatrics 102:720–722
    [Google Scholar]
  16. Kurtzman G. J., Cohen B. J., Field M. A., Oseas R., Blaese M., Young N. 1989; Immune response to B19 parvovirus and an antibody defect in persistent viral infection. Journal of Clinical Investigation 84:1114–1123
    [Google Scholar]
  17. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature; London: 227680–685
    [Google Scholar]
  18. Makoff A. J., Ballantine S. P., Smallwood A. E., Fairweather N. F. 1989; Expression of tetanus toxin fragment C in E. coli: its purification and potential use as a vaccine. Bio/Technology 7:1043–1046
    [Google Scholar]
  19. Morinet F., D’Auriol L., Tratschin J. D., Galibert F. 1989; Expression of the human parvovirus B19 protein fused to Protein A in Escherichia coli: recognition by IgM and IgG antibodies in human sera. Journal of General Virology 70:3091–3097
    [Google Scholar]
  20. Ozawa K., Young N. 1987; Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. Journal of Virology 61:2627–2630
    [Google Scholar]
  21. Ozawa K., Ayub J., Yu-Shu H., Hurtzman G., Shimada T., Young N. 1987; Novel translation map for the B19 (human) pathogenic parvovirus. Journal of Virology 61:2395–2406
    [Google Scholar]
  22. Ozawa K., Ayub J., Young N. 1988; Translational regulation of B19 parvovirus capsid production by multiple upstream AUG triplets. Journal of Biological Chemistry 263:10922–10926
    [Google Scholar]
  23. Pattison J. R., Jones S. E., Hodgson J., Davis L. R., White J. M., Stroud C. E., Murtaza L. 1981; Parvovirus infections and hypoplastic crisis in sickle cell anaemia. Lancet i:664–665
    [Google Scholar]
  24. Porter H. J., Khong T. Y., Evans M. F., Chan V. T.-W., Fleming K. A. 1988; Parvovirus as a cause of hydropsfetalis: detection by in situ DNA hybridization. Journal of Clinical Pathology 41:381–383
    [Google Scholar]
  25. Rao K. R., Patel A. R., Anderson M. J., Hodgson J., Jones S. E., Pattison J. R. 1983; Infection with parvovirus-like virus and aplastic crisis in chronic hemolytic anemia. Annals of Internal Medicine 98:930–932
    [Google Scholar]
  26. Reid D. M., Brown T., Reid T. M. S., Rennie J. A. N., Eastmon C. J. 1985; Human parvovirus associated arthritis. A clinical and laboratory description. Lancet i:422
    [Google Scholar]
  27. Schwartz T. F., Roggendorf M., Deinhardt F. 1988; Human parvovirus B19: ELISA and immunoblot assays. Journal of Virological Methods 20:155–168
    [Google Scholar]
  28. Sergeant G. R., Mason K., Topley J. M., Sergeant B. E., Pattison J. R., Jones S. E., Mohamed R. 1981; Outbreak of aplastic crisis in sickle cell anaemia associated with parvovirus-like agent. Lancet ii:595–597
    [Google Scholar]
  29. Shade R. O., Blundell M. C., Cotmore S. F., Tattersall P., Astell C. R. 1986; Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. Journal of Virology 58:921–936
    [Google Scholar]
  30. Sisk W. P., Berman M. L. 1987; Expression of human parvovirus B19 structural protein in E. coli and detection of antiviral antibodies in human serum. Bio/Technology 5:1077–1080
    [Google Scholar]
  31. Towbin H., Staehelin T., Gordon J. 1979; Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences, U.S.A 76:4350
    [Google Scholar]
  32. Twigg A. J., Sherratt D. J. 1980; Trans-complementable copy-number mutants plasmid ColE1. Nature; London: 283216–218
    [Google Scholar]
  33. West N. C., Meigh R. E., Mackie M., Anderson M. J. 1986; Parvovirus infection associated with aplastic crises in a patient with HEMPAS. Journal of Clinical Pathology 39:1019–1020
    [Google Scholar]
  34. Winther M. D., Allen G., Bomford R. H., Brown F. 1986; Bacterially expressed antigenic peptide from foot-and-mouth disease virus capsid elicits variable immunologic responses in animals. Journal of Immunology 136:1835–1840
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-71-11-2665
Loading
/content/journal/jgv/10.1099/0022-1317-71-11-2665
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error